Chemomab Therapeutics (CMMB) Tops Q4 EPS by 5c

Chemomab Therapeutics (NASDAQ: CMMB) reported Q4 EPS of ($0.01), $0.05 better than the analyst estimate of ($0.06).

For earnings history and earnings-related data on Chemomab Therapeutics (CMMB) click here.

You May Also Be Interested In

• Deere conference call: 2027 orders up mid-single digits from last year)
• SentinelOne Inc (S) PT Raised to $26 at Cantor Fitzgerald Following Strong Q2 Checks
• Bernstein upgrades Analog Devices on Q3 beat, improving risk-reward